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K e y  M e s s a g e s 
1. Protocadherin 10 (PCDH10) is silenced in 
endometrioid endometrial cancer through 
promoter hypermethylation. 
2. Ectopic expression of PCDH10 inhibits tumour 
growth and induces cell apoptosis.
3. Transcriptomic analysis revealed that PCDH10 
expression down-regulates metastasis-associated 
lung adenocarcinoma transcript 1 (MALAT1). 
Further mechanistic studies uncovered that 
MALAT1 expression is transcriptionally induced 
by Wnt/β-catenin signalling.
4. We uncovered a novel PCDH10-Wnt/β-catenin-
MALAT1 regulatory axis that contributes to 
development and progression of endometrioid 
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Introduction
Endometrioid endometrial cancer (EEC) accounts 
for 80% to 90% of all endometrial cancers. Its key 
mutational events have been characterised, but the 
underlying molecular mechanisms remain poorly 
elucidated. We discovered a novel mir-193-YY1-
APC regulatory axis that exerts functional roles in 
EEC development.1 In this study, we investigated 
the tumour suppressive function of protocadherin 
10 (PCDH10) in EEC. PCDH10 was proposed as a 
tumour suppressor, and its inactivation secondary 
to promoter hypermethylation has been detected 
in multiple cancers. Restoration of PCDH10 could 
inhibit cell growth, reduce clonogenicity, restrain 
cell invasion, and induce cell apoptosis.2 The link 
between PCDH10 and EEC is unknown, and the 
molecular mechanisms await exploration. LncRNAs 
are RNA species over 200 nucleotides in length 
and play an important role in transcriptional 
regulation. LncRNAs are deregulated in different 
cancer contexts, including metastasis-associated 
lung adenocarcinoma transcript 1 (MALAT1). 
Since its discovery as a prognostic factor for 
lung cancer metastasis, MALAT1 has been 
shown to be broadly up-regulated in a variety of 
cancer entities and to play critical roles in distinct 
cancer hallmark capabilities.3 However, study of 
MALAT1 function in EEC is still lacking, and the 
transcriptional regulation of MALAT1 expression 
and the causes behind its deregulation are barely 
explored.
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Methods
A total of 76 cases of primary EEC and 45 cases of 
normal tissues were used in this study. All specimens, 
clinical information, and procedures were approved 
by the Clinical Research Ethics Committee of The 
Chinese University of Hong Kong.
 In a xenograft mouse model, 5 × 106 of control 
or PCDH10 stably expressing HEC-1-B cells were 
subcutaneously injected into the left and right flanks 
of the female athymic nude mice (n=5 for each 
group). All animal experiments were approved by 
Animal Experimentation Ethics Committee of The 
Chinese University of Hong Kong.
 Human EEC cell lines were obtained from 
American Tissue and Cell Culture and cultured as 
recommended.
 A 516 bp fragment harbouring TCF4 binding 
site was amplified from genomic DNA and cloned 
into pGL3-basic vector. The mutant reporter was 
generated by mutating the TCF4 binding motif from 
CTTTGAA to CTTTGCG.
 An RNA antisense probe was in vitro 
transcribed corresponding to 6871-7224 bp of 
MALAT1 (RefSeq accession, NR_002819).
 ChIP assays were carried out as described 
previously.4 5 µg of antibodies against β-catenin or 
equal amount isotype IgG was used for each 2 × 107 
cell per ChIP. Immunoprecipitated genomic DNA 
was resuspended in 15 µL of water. PCR was then 
performed with 1 µL of DNA as a template on a 
7900HT system.
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 The difference of PCDH10 mRNA expression 
between tumour and adjacent non-tumour tissues 
was analysed by the Mann-Whitney U test. For 
analysing the association of MALAT1 ISH scoring 
with clinical parameters, Pearson’s Chi-square 
test was used. Statistical significance between two 
groups was assessed by Student’s t-test. All tests 
were two sided, and a P value of <0.05 was considered 
statistically significant.
Results
PCDH10 is down-regulated in EEC through 
promoter hypermethylation
We examined PCDH10 mRNA expression in EEC 
cells lines and micro-dissected EEC tumour samples 
using normal endometrial tissue as controls. 
PCDH10 was significantly down-regulated in 76 
tumour samples and all five cell lines, compared 
with 45 normal controls (Fig 1a). Aberrant 
hypermethylation in a CpG island (+8 ~ -328 bp 
upstream TSS) of PCDH10 promoter was detected in 
EEC tumours but not in normal endometrial tissues 
(Fig 1b). This finding was confirmed by analysing the 
genome-wide methylation data generated by The 
Cancer Genome Atlas project. Our analysis results 
from a cohort of 208 EEC patients and 34 normal 
controls showed a marked hypermethylation on the 
above region of PCDH10 promoter in EEC samples. 
Consistently, when treated with demethylation 
agent, 5-Aza, the promoter hypermethylation 
was markedly reduced and PCDH10 expression 
was restored (Fig 1c). Collectively, these results 
demonstrated that PCDH10 is down-regulated in 
EEC through its promoter hypermethylation.
PCDH10 restoration inhibits proliferation 
and induces apoptosis in EEC cells
We performed gain-of-function study by 
overexpressing PCDH10 in EEC cells. Successful 
restoration of PCDH10 was found to inhibit cell 
proliferation as revealed by cell counting and 
MTS assay (Fig 1d). Furthermore, overexpression 
of PCDH10 impeded their abilities to grow in 
an attachment-independent manner (Fig 1e). In 
addition, a marked increase in the number of subG1 
cells was detected in both AN3CA and HEC-1-B 
cells (Fig 1f ), suggesting that PCDH10 may lead 
to cell apoptosis. Consistently, the Annexin V-PI 
double staining and TUNEL assays revealed that the 
number of apoptotic cells was significantly increased 
upon PCDH10 overexpression. Collectively, these 
results concluded that PCDH10 is a pro-apoptotic 
factor in EEC cells.
RNA-sequencing reveals MALAT1 as a 
downstream factor of PCDH10
We performed a genome-wide analysis to globally 
characterise PCDH10-affected transcriptomic 
changes. Among all potential targets, MALAT1 is 
one of the most significant targets downregulated 
upon overexpression of PCDH10. MALAT1 is well 
known to have an oncogenic role and involved in 
diverse processes of cancer development including 
cell proliferation, apoptosis, migration, and 
metastasis; nevertheless, its role in EEC has not been 
investigated. MALAT1 is abundantly expressed in 
EEC cells thus making the functional study relatively 
easy and feasible in a short period of time. MALAT1 
is well studied in many systems and necessary 
reagents are relatively easy to obtain 
 The RNA-seq data revealed that MALAT1 
was decreased by approximately 70% in PCDH10 
expressing cells (Fig 1g), which is further validated 
by independent qRT-PCR analyses (Fig 1h). To test 
whether MALAT1 is functionally downstream of 
PCDH10, we examined the effect of MALAT1 by 
using two siRNAs. Successful decrease of MALAT1 
led to a significant delay in cell proliferation as 
revealed by cell counting assay and MTS assay (Fig 
2a). Furthermore, siMALAT1 treatment induced 
a striking increase in apoptotic cell population 
(Fig 2b). Altogether the above findings suggested 
that MALAT1 knockdown phenocopied PCDH10 
overexpression effect in EEC cells. Overexpression of 
MALAT1 reversed the inhibitory effect of PCDH10 
on EEC cell growth (Fig 2c).
PCDH10 suppresses MALAT1 transcription 
through inhibiting WNT/β-catenin 
signalling
PCDH-gamma was found to negatively regulate 
Wnt/β-catenin signalling.5 We speculated that 
loss of PCDH10 may induce MALAT1 expression 
through activation of Wnt signalling. We examined 
the effect of PCDH10 restoration on Wnt signalling. 
PCDH10 overexpression caused a sharp decrease 
of several Wnt targets, including LEF1, TCF1, and 
c-MYC (Fig 2d) as well as Wnt signalling reporter 
activity (Fig 2e). Stimulation of Wnt signalling 
by lithium chloride led to a mild but significant 
increase of MALAT1 expression (Fig 2f ). Moreover, 
we analysed publicly available TCF4 ChIP-seq data 
generated from various cell lines. In all the five cell 
lines, two TCF4 binding peaks proximal to the TSS 
of MALAT1 were detected and a consensus binding 
motif of TCF4 was found in the promoter region 
(+78 to +88 bp) [Fig 2g]. We cloned this region into a 
luciferase reporter (wild type) and found its activity 
was induced upon lithium chloride treatment; 
however, the response was lost when the TCF 
binding site is mutated (Mut) [Fig 2h]. Furthermore, 
PCDH10 over-expression could suppress the wild 
type but not the Mut activities (Fig 2i), suggesting 
PCDH10 regulates MALAT1 transcription through 
inhibiting Wnt signalling. We performed ChIP 
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FIG 1.  PCDH10 is down-regulated in endometrioid endometrial cancer (EEC) cells through promoter hypermethylation and 
functions to inhibit EEC cell proliferation and to induce cell apoptosis. (a) Expression of PCDH10 in microdissected normal 
endometrial tissues (NE, n=45), EEC primary tumours (EEC, n=76), and five EEC cell lines. (b) Methylation status of CpG sites in the 
PCDH10 promoter in 8 normal endometrial and 8 EEC samples assayed by bisulfate genomic sequencing. A 336-bp region (-328 
~ +8) spanning the core promoter harbouring 27 CpG sites was analysed. The degree of methylation was measured as percentage 
of methylated cytosines from seven randomly sequenced colonies. (c) Relative PCDH10 expression levels in five EEC cell lines 
treated with 5-Aza for the indicated times. (d) Cell proliferation in the above transfected cells was measured by MTS assay. (e) 
Monolayer colony formation assay was performed in the above control or PCDH10 expressing cells. The number of colonies was 
counted from three independent experiments. (f) Relative cell numbers in each cell cycle phase were determined by FACS of the 
PI-stained staining vector control or PCDH10 expressing cells. Percentages of cells in each phase (G1, S, G2, subG1) are represented. 
(g) Differential expression of MALAT1 transcripts determined by RNA-seq, shown as wiggle tracks on the UCSC genome browser. 
The expression values of MALAT1 in FPKM. (h) MALAT1 RNA expression was measured in AN3CA and HEC-1-B cells expressing 
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FIG 2.  MALAT1 is a functional downstream of PCDH10 and PCDH10 inhibits MALAT1 transcription through Wnt/β-catenin 
signalling pathway. (a) Depletion of MALAT1 by siRNA oligos in AN3CA and HEC-1-B cells. Two siRNAs targeting MALAT1 
(siMALAT1A and siMALAT1B) were used with a scramble sequence as control (siNC). Proliferation of the above transfected cells 
was determined by MTS assay. (b) Cell apoptosis was determined by TUNEL assay in AN3CA and HEC-1-B cells transfected with 
siMALAT1 or siNC. The index of TUNEL-positive cells is calculated. (c) HEC-1-B cells stably expressing PCDH10 or control vector 
were transiently transfected with MALAT1 expressing or a vector control plasmid, respectively. Cell proliferation was measured 
using MTS value at the indicated days after seeding. (d) PCDH10 decreases the mRNA expression levels of c-Myc, LEF1 and 
TCF1, in both AN3CA and HEC-1-B cells. (e) Transient expression of PCDH10 inhibits TOP-flash luciferase reporter activity in the 
above cells. (f) Expression of MALAT1 was increased by lithium chloride treatment; c-Myc, LEF1 or TCF1 expression was used as 
positive controls. (g) Schematic illustration of the promoter region of MALAT1 gene. The predicted TCF4 binding site with genomic 
location (+78 ~ +88) was displayed; wild type, mutant, and the consensus TCF binding sequences were indicated below. (h) Lithium 
chloride treatment increased the activity of the wild type but not the Mut reporter. (i) PCDH10 inhibits the wild type but not the 
Mut reporter. Values were normalised by renilla levels. (j) ChIP-PCR detection of the β-catenin enrichment on the TCF binding site 
in HEC-1-B cells stably expressing PCDH10 or vector control. c-Myc genomic region harbouring a TCF binding site was used as a 
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to detect β-catenin enrichment on MALAT1 
promoter. Expectedly, a robust enrichment of 
β-catenin was found on the identified TCF4 site 
and the enrichment was significantly diminished 
upon PCDH10 overexpression (Fig 2j). Together, 
these data demonstrated that PCDH10 suppresses 
MALAT1 expression through impairing β-catenin 
binding to its promoter.
FIG 3.  PCDH10-MALAT1 regulatory axis in vivo. (a) PCDH10 attenuates subcutaneous tumour growth in a mouse xenograft 
model. Relative tumour volumes are shown with respect to day 0 where the volumes were set to 1. (b) Mice were sacrificed 
at the end of the treatment and images were taken along with the dissected tumours from three representative mice. (c) In situ 
cell apoptosis in xenograft tumours was determined by TUNEL staining of the tumour sections. (d) Knockdown of MALAT1 by 
intratumoural injection of siRNA oligos inhibits subcutaneous tumour growth in a mouse xenograft model. (e) Images of mice and 
the dissected tumours were taken at the end of the treatment. (f) The expression of MALAT1 and c-Myc was decreased in PCDH10 
xenograft tumours. (g) In situ hybridisation (ISH) detection of MALAT1 RNA in normal endometrial tissues and endometrioid 
endometrial cancer (EEC) patient samples. Representative images with various levels of staining (negative from normal tissue, 
weak, moderate or strong from tumour tissues). (h) The association of the ISH staining scores with grades of tumour (1/2 or 3). 
(i) IHC staining of β-catenin and ISH staining of MALAT1 on sequential sections of 37 EEC specimens. Representative β-catenin 
and MALAT1 staining images are shown in three EEC cases MALAT1 and nuclear β-catenin staining levels above were scored and 
the anti-correlation between MALAT1 ISH score and nuclear β-catenin IHC score in 37 EEC samples was shown. (j) A model of 
PCDH10-Wnt/β-catenin-MALAT1 axis in EEC development. In EEC tumours, the promoter region of PCDH10 is highly methylated, 
resulting in the down-regulation of PCDH10, which subsequently induces the expression of MALAT1 through activating Wnt/
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PCDH10-MALAT1 regulatory axis in vivo
We evaluated the function of PCDH10-MALAT1 
regulatory axis in vivo. We found PCDH10 
overexpression markedly delayed tumour growth 
(n=5, P<0.01, Fig 3a, b) and caused a severe cell 
apoptosis in vivo (Fig 3c), which was in agreement 
with its pro-apoptotic effect. To illustrate the 
effect of MALAT1, siRNA oligos were injected 
into the HEC-1-B xenograft tumour. A comparable 
phenotype as PCDH10 over-expression could 
be observed in siMALAT1 group (Fig 3d, e). We 
also detected reduced level of both MALAT1 and 
c-Myc in PCDH10 overexpressing tumours (Fig 3f ), 
suggesting the existence of PCDH10-Wnt-MALAT1 
axis in the xenografts. 
 To validated the above findings in EEC clinical 
samples, we examined the MALAT1 expression by 
in situ hybridisation on the paraffin sections. A much 
higher level was found in EEC samples as compared 
with normal tissues (Fig 3g). In addition, a strong 
MALAT1 signalling appeared to be associated with 
low histologic grade (grade 1/2 versus 3) [P=0.028, 
Fig 3h].
 Analyses of tissue microarray data revealed 
that high expression of MALAT1 was linked with 
hyperplasia (P=0.017), menopausal status (P=0.028), 
no recurrence (P=0.032), and low metastasis potential 
(P=0.041). Further exploring The Cancer Genome 
Atlas data from a large cohort of EEC samples 
(n=253), we detected a reverse association between 
PCDH10 and MALAT1 (P=0.0324). Additionally, the 
expression level of MALAT1 by ISH staining is found 
strongly correlated with the total or nuclear level of 
β-catenin by IHC staining (Fig 3i). Altogether, these 
analyses confirmed the presence of PCDH10-Wnt/β-
catenin-MALAT1 regulation in clinical samples.
Discussion
We identified PCDH10 as a tumour suppressor in 
EEC. Our results showed that PCDH10 promoter is 
hypermethylated through analysis of locally collected 
EC samples and analysing The Cancer Genome 
Atlas data from worldwide EEC samples. Functional 
studies revealed that restoration of PCDH10 
successfully reduced cell growth and induced cell 
apoptosis, in keeping with what was uncovered in 
other cancers. Notably, we could not recapitulate 
all functional features of PCDH10 demonstrated 
in other studies and the impact of PCDH10 on cell 
cycle also differs between two EEC cell lines, which 
may reflect cell type and cancer type specific roles of 
PCDH10.
 Our findings uncovered the transcriptomic 
influence exerted by PCDH10. Moreover, we 
identified MALAT1 as a functional downstream 
target of PCDH10 and showed that MALAT1 plays 
an oncogenic role in EEC. We demonstrated that 
MALAT1 is positively associated with hyperplasia, 
and negatively with metastasis, suggesting its 
predictive value as a molecular biomarker. The 
positive correlation of MALAT1 with hyperplasia 
and low grade EEC implies that dysregulation of 
MALAT1 is an early event in EEC development.
 We provide novel insights into how PCDH10 
acts on MALAT1 through modulating Wnt/β-
catenin signalling. We identified MALAT1 as a direct 
transcriptional target of Wnt/β-catenin in EEC cells. 
According to ChIP-seq data from ENCODE, the TCF 
binding on this site is present in multiple cancer cell 
lines, thus Wnt regulation of MALAT1 likely occurs 
as a general pathway in various cancers.
 Collectively, we identified a novel regulatory 
axis, PCDH10-Wnt-MALAT1 in the effort of 
elucidating the tumour suppressive function of 
PCDH10 (Fig 3j) and showed PCDH10 and lncRNA 
function in EEC and elucidated the transcriptional 
regulation of MALAT1.
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